A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Seong-Wook | - |
dc.contributor.author | Kim, Ji-Min | - |
dc.contributor.author | Han, Dong-Gyun | - |
dc.contributor.author | Geum, Dongho | - |
dc.contributor.author | Yun, Hwayoung | - |
dc.contributor.author | Yoon, In -Soo | - |
dc.date.accessioned | 2021-08-30T04:02:49Z | - |
dc.date.available | 2021-08-30T04:02:49Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2021-01-15 | - |
dc.identifier.issn | 1570-0232 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50095 | - |
dc.description.abstract | Alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, is an oral anticancer agent approved for the treatment of advanced or metastatic breast cancer. In this study, a sensitive bioanalytical method using high-performance liquid chromatography combined with a fluorescence detector (HPLC-FLD) was developed for the determination of alpelisib in rat plasma. This newly developed method was validated in terms of linearity (1-1,000 ng/mL), precision, accuracy, recovery, matrix effect, and stability according to the US Food and Drug Administration guideline and these parameters were within the acceptable limits. Alpelisib tended to be stable in plasma, urine, simulated intestinal fluid, and buffer with pH > 4.0 for 24 h, but in the pH 1.2 buffer and simulated gastric fluid for up to 4 h only. A study involving intravenous administration of alpelisib in rats showed that the dose normalized area under the plasma concentration versus time curve (AUC) of alpelisib changed significantly as the dose increased from 1 to 10 mg/kg. Similarly, an oral rat study indicated that the dose-normalized AUC and the fraction of dose that remained in the gastrointestinal (GI) tract changed significantly as the dose increased from 0.5 to 10 mg/kg. These nonlinear (dose-dependent) pharmacokinetics of intravenous and oral alpelisib could be attributed to the saturation of ubiquitous metabolism among most tissues and/or GI absorption processes. To the best of our knowledge, this is the first study to investigate the in vivo nonlinear pharmacokinetics of alpelisib and its possible mechanisms, together with a new HPLC-FLD method to determine alpelisib in biological matrices. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | PI3K/AKT/MTOR PATHWAY | - |
dc.subject | DOCETAXEL | - |
dc.subject | STRATEGY | - |
dc.subject | BYL719 | - |
dc.subject | MS/MS | - |
dc.title | A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Geum, Dongho | - |
dc.identifier.doi | 10.1016/j.jchromb.2020.122508 | - |
dc.identifier.scopusid | 2-s2.0-85099643774 | - |
dc.identifier.wosid | 000612822400008 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, v.1163 | - |
dc.relation.isPartOf | JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | - |
dc.citation.title | JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | - |
dc.citation.volume | 1163 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.subject.keywordPlus | PI3K/AKT/MTOR PATHWAY | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | STRATEGY | - |
dc.subject.keywordPlus | BYL719 | - |
dc.subject.keywordPlus | MS/MS | - |
dc.subject.keywordAuthor | Alpelisib | - |
dc.subject.keywordAuthor | HPLC-FLD | - |
dc.subject.keywordAuthor | Nonlinear pharmacokinetics | - |
dc.subject.keywordAuthor | Ubiquitous metabolism | - |
dc.subject.keywordAuthor | GI absorption | - |
dc.subject.keywordAuthor | Rat | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.